What the New Controlled Substances Regulations (SOR/2025-242) Mean for Manufacturers and Dealers

A practical breakdown of Canada's biggest controlled substances reform in decades — what changes on October 1, 2026, and how to be ready.

What Is SOR/2025-242?

SOR/2025-242, formally titled the Controlled Substances Regulations, was registered on November 28, 2025, by Order in Council P.C. 2025-840, and published in the Canada Gazette, Part II, Volume 159, Number 26 on December 17, 2025. The regulations were made by the Governor General in Council on the recommendation of the Minister of Health under subsection 55(1) of the Controlled Drugs and Substances Act (CDSA).

In plain language, the CSR is Health Canada's long-anticipated consolidation of Canada's controlled substances framework into a single, modernized regulation. Until October 1, 2026, the existing regulations remain in force. After that date, the new framework governs every aspect of the controlled substances lifecycle — from dealer licensing and transactional records, through prescriptions, hospital handling, government laboratory activities, and personal-use exemptions.

The reform is significant for one practical reason: for the first time in Canadian regulatory history, narcotics, controlled drugs, targeted substances, and restricted drugs are governed by a single, harmonized rulebook. The Schedules to the CSR (Schedules 1 through 4) preserve the four traditional substance categories, but the operational requirements — security, reporting, recordkeeping, destruction, import and export — now share one consistent architecture.

Why Now? The Consolidation Rationale

Canada has regulated controlled substances through a patchwork of instruments for decades. A licensed dealer producing a Schedule I narcotic, a Schedule II controlled drug, and a Schedule IV benzodiazepine at the same site previously navigated three separate regulations, often with overlapping but inconsistent requirements for security, recordkeeping, and reporting. Health Canada's stated objective is to eliminate that friction — to clarify what compliance looks like, reduce administrative duplication, and modernize oversight tools.

For most licence holders, the rationale is welcome. The reality, however, is that consolidation does not mean dilution. The CSR introduces stricter reporting cadences, tighter qualification standards for designated persons, and clearer enforcement levers. Companies that have been operating comfortably under the old regime should not assume that their existing systems, SOPs, and personnel structures will transfer cleanly into the new framework.

The Big Operational Shift: From Annual to Monthly Reporting

Of every change introduced by SOR/2025-242, this is the one most likely to disrupt day-to-day operations.

Under the previous regulations, licensed dealers submitted an annual report on regulated activities — sufficient time to reconcile inventory, address gaps, and refine narratives before submission.

Under the CSR, licensed dealers will be required to submit monthly reports on regulated activities. That is a twelvefold increase in submission cadence — and, more importantly, a fundamental change in the operational rhythm of compliance.

What this means in practice:

• Inventory reconciliation cycles must compress. A monthly close requires that physical counts, receipts, dispositions, packaging, production, and destruction records all be reconciled within days of month-end, not weeks.
• Data infrastructure becomes critical. Manual spreadsheets that supported annual reporting will struggle to support monthly cadence at scale. Many dealers will need to upgrade ERP, inventory management, or compliance software — and validate those systems before October 1.
• Personnel capacity must be reviewed. Compliance, quality assurance, and finance functions will all see workload increases. Staffing models built around annual peaks will need to flatten.
• Reporting governance must tighten. A monthly report submitted in haste — with errors or omissions — creates a record that compounds risk over time. Each monthly submission is a potential inspection trigger.

Importantly, the CSR clarifies what stays outside the monthly report. Unexplainable losses and thefts are not bundled into monthly submissions. They retain their own urgent reporting timelines:

• Loss of a controlled substance that cannot be explained on the basis of normally accepted business activities — a written report to the Minister within 72 hours of becoming aware.
• Theft — a written report to a police force within 24 hours, and a written report to the Minister within 72 hours.
• Suspicious transactions that may relate to diversion to an illicit market or use — a written report to the Minister within 72 hours.
• Loss or theft of a licence or permit — a written report to the Minister within 72 hours.

The New Licensing Structures

The second major shift is structural. SOR/2025-242 replaces the prior substance-specific licence regimes with a unified dealer's licence framework.

Who Needs a Dealer's Licence?

A dealer's licence is required for any person who, at a given site, intends to:

• Produce a controlled substance (with limited exemptions for pharmacists or government laboratories);
• Package, sell, provide, deliver, send, or transport a controlled substance (with carved-out authorizations for pharmacists, practitioners, hospitals, the Minister, and certain individuals);
• Import or export a controlled substance (with exemptions for the Minister, government laboratories, and certain individuals); or
• Destroy a controlled substance, where destruction is the only activity intended.

Designated Roles: Senior Person in Charge and Qualified Person in Charge

The CSR formalizes — and harmonizes across all substance categories — the requirement for two designated individuals at every licensed site:

1. Senior Person in Charge (SPIC) — one individual with overall responsibility for management of activities involving controlled substances at the site.
2. Qualified Person in Charge (QPIC) — one individual who supervises day-to-day activities and is accountable for ensuring compliance with the CSR, the licence, and any associated permits. An Alternate QPIC may also be designated.

The QPIC qualifications are explicit and non-trivial. The individual must work at the site, hold a recognized post-secondary credential in a relevant discipline — pharmacy, medicine, dentistry, veterinary medicine, pharmacology, chemistry, biology, pharmacy technician, laboratory technician, pharmaceutical regulatory affairs, supply chain management, or security — or a foreign equivalent with an equivalency assessment, and demonstrate sufficient knowledge and experience to carry out the role.

For many smaller dealers and emerging biotech or pharmaceutical companies, identifying a fully qualified QPIC who is willing to assume legal accountability is one of the most underestimated parts of CSR readiness.

Licence Validity and Scope

A CSR dealer's licence will specify the licensed activities and specific controlled substances covered, the site municipal address, the security level (determined in accordance with Health Canada's Security Directive), an expiry date of up to a maximum of three years, and any terms and conditions including production quantities and time periods. Licences are tied to a single site; multi-site operators will hold multiple licences with site-specific terms, security determinations, and personnel.

New Ministerial Powers: Partial Suspension

One quiet but consequential change: the Minister of Health is now authorized to partially suspend a dealer's licence — narrowing it to specific activities or specific substances, rather than only fully suspending or revoking it. In practical terms, this gives Health Canada a more proportionate enforcement tool. From the licensee's perspective, it means that a single non-compliance in one corner of operations can be carved out and shut down without halting the entire business. Incident response, CAPA, and documentation discipline matter more than ever.

Hospitals, Government Laboratories, Pharmacists, and Individuals

The CSR is not just about dealers. It reshapes obligations across the ecosystem.

Hospitals gain a clearer framework through the new definition of "person in charge of a hospital" — an individual with responsibility for managing all of a hospital's controlled substances activities. Hospitals can now sell or provide controlled substances to practitioners for emergency purposes, to licensed dealers, or to the Minister, and may destroy controlled substances on site or send them to a licensed dealer specialized in destruction.

Government laboratories receive a new authorization to produce, sell, provide, send, deliver, transport, import, or export controlled substances without a dealer's licence, though import and export permits remain required. This exemption applies only to government-operated laboratories, not to private or contract research laboratories.

Pharmacists and pharmacy technicians are governed under a dedicated part of the CSR, with provisions covering compounding, prescription transfers, and prescription extensions consolidated into one place.

Individuals gain a longer 90-day personal-use window for importing or exporting controlled substances other than restricted drugs — an expansion from the 30-day limit that has historically applied to narcotics and controlled drugs under section 56(1) CDSA exemptions. Individuals can also now lawfully deliver a prescription drug containing a controlled substance to a patient and bring a controlled substance to a retail pharmacy for destruction.

Cannabis Regulations Harmonization (SOR/2025-244)

The CSR does not stand alone. Companion regulation SOR/2025-244 amends the Cannabis Regulations to align with the CSR. Notable amendments include:

• Revised master grower responsibilities;
• Allowances for pharmacists to distribute drugs containing cannabis for the purpose of destruction to licensed dealers and to other pharmacists for prescription fulfilment;
• A new requirement for cannabis licence holders and licensed dealers to record the drug identification number (DIN) for prescription drugs containing cannabis when conducting activities such as import, sale, and distribution.

If your business holds both a cannabis licence and a controlled substances dealer licence — or operates at the intersection (e.g., cannabis-derived prescription products) — you will need to read SOR/2025-242 and SOR/2025-244 together, not separately.

Practical Steps Before October 1, 2026

1. Gap Analysis Against the CSR (Q2–Q3 2026). Map every existing SOP, record, system, and personnel role to the corresponding CSR requirement. Identify where current practice falls short, where it exceeds, and where the rule has fundamentally changed (e.g., reporting cadence).

2. Personnel Reviews and Designations (Q2–Q3 2026). Confirm — in writing — your Senior Person in Charge and Qualified Person in Charge designations. Verify QPIC credentials against the CSR's qualification list. Do not assume your existing licence will simply transfer.

3. Reporting Infrastructure Build (Q3 2026). Design your monthly reporting workflow end-to-end: data sources, reconciliation cadence, internal sign-off, escalation paths, and submission method. Run a parallel "shadow" monthly close for two or three months before October 1 to surface gaps.

4. Security Review (Q2–Q3 2026). Re-confirm your site security against the Security Directive. The CSR explicitly ties licence issuance and renewal to security compliance.

5. SOP Refresh and Training (Q3 2026). Rewrite the affected SOPs — recordkeeping, loss and theft reporting, destruction protocols, transportation, import and export declarations, suspicious transaction reporting. Retrain affected personnel and document the training.

6. Recordkeeping and Document Retention (Ongoing). Confirm that records can be retrieved on inspection within required timelines.

7. Mock Inspection (August or September 2026). Conduct an internal or third-party mock Health Canada inspection against CSR standards. Treat it as the dress rehearsal it is.

8. Day-One Readiness Plan (September 2026). Define exactly what will happen on October 1, 2026 — which systems flip over, who owns the first monthly report, and how exceptions will be escalated.

Common Pitfalls and How to Avoid Them

In two decades of regulatory consulting across pharmaceuticals, cannabis, natural health products, and controlled substances, certain compliance pitfalls repeat. The CSR transition will be no different. Watch for:

• Treating consolidation as simplification. It is not. Consolidation removes inconsistency, but the underlying rigour is preserved or tightened.
• Underestimating the monthly reporting build. A monthly close needs people, systems, and governance. None of that materializes the week before October 1.
• Assuming current QPIC designations carry forward unchanged. The CSR's qualification framework is explicit. Verify.
• Letting security drift. Security level determinations under the Security Directive will be re-examined as part of the transition.
• Ignoring the cannabis interaction. If you handle prescription drugs containing cannabis, your DIN recordkeeping must be airtight.
• Failing to document the transition itself. A clean paper trail of how you analyzed the CSR, decisions made, and changes implemented is one of the strongest defences in an early-period inspection.

How MFLRC Guides Clients Through the CSR Transition

This is exactly the kind of regulatory inflection point MFLRC was built for. Twenty-plus years of senior-led practice across pharmaceuticals, cannabis, controlled drugs, and adjacent sectors means we have walked clients through every comparable transition in the last two decades — from the original implementation of the Cannabis Regulations to revisions under the Food and Drug Regulations.

Our Regulatory Affairs, Licensing & Import/Export practice handles the strategic side — licence pathway analysis, application drafting, terms and conditions negotiation, transitional approvals, and ongoing notifications.

Our Quality Assurance Services team builds and refreshes the QMS architecture you need for CSR compliance — SOPs, record systems, designated person frameworks, batch and lot controls, and the documentation discipline inspectors expect.

Our Audit Services practice runs gap analyses, mock inspections, and CAPA programs that turn a regulatory transition into a measurable readiness curve.

And our Pharmaceutical Validation Services function supports the data integrity, computerized system validation, and analytical method work that monthly reporting at scale requires.

Every engagement is led by a senior regulatory consultant with direct Health Canada experience. We don't sell checklists. We build defensible compliance.

Frequently Asked Questions

What is SOR/2025-242?

SOR/2025-242 is the Controlled Substances Regulations, a new federal regulation made under the Controlled Drugs and Substances Act that consolidates Canada's framework for narcotics, controlled drugs, targeted substances, and restricted drugs into a single rulebook. It comes into force on October 1, 2026.

When does SOR/2025-242 come into force?

October 1, 2026. Until that date, the existing regulations — the Narcotic Control Regulations, the Benzodiazepines and Other Targeted Substances Regulations, and Parts G and J of the Food and Drug Regulations — remain in effect.

Will my existing dealer's licence transfer automatically?

Health Canada has indicated that regulated parties should make adjustments to comply with the new requirements. Specific transitional treatment of existing licences should be confirmed against Health Canada guidance and notices issued ahead of October 1, 2026. MFLRC monitors this guidance and updates our clients in real time.

What does monthly reporting require?

Licensed dealers must submit monthly reports on regulated activities — production, packaging, sales, imports, exports, and similar — instead of the prior annual cycle. Loss and theft reporting remain separate, with their own 72-hour and 24-hour timelines.

Do I need to re-qualify my Qualified Person in Charge?

Almost certainly, yes — at minimum to confirm that current designations meet the explicit CSR qualification framework. Existing QPICs from prior regulations should be re-mapped against the CSR's credential and experience requirements.

What happens if I am not ready by October 1, 2026?

Non-compliance with controlled substances regulations carries serious consequences under the CDSA — including suspension, revocation, and prosecution. The Minister also now has new partial suspension powers under the CSR. Readiness is not optional.

Does the CSR change anything for cannabis operators?

Yes. SOR/2025-244 amends the Cannabis Regulations in parallel to harmonize with the CSR, including changes to master grower responsibilities and recordkeeping requirements for prescription drugs containing cannabis.

How can MFLRC help?

MFLRC offers end-to-end support — gap analysis, SOP development, QPIC framework design, monthly reporting workflow build, security review, mock inspection, and ongoing post-October compliance monitoring. Contact us at +1-647-492-5301 or info@mflrc.com.

Don't Wait for the Inspector to Tell You What You Missed

October 1, 2026 will arrive whether you are ready or not. The companies that emerge cleanly from this transition will be the ones that started early, treated consolidation as a serious overhaul rather than a paperwork swap, and built defensible compliance from the documentation up.

If you handle controlled substances in Canada — as a manufacturer, dealer, distributor, hospital, laboratory, or pharmaceutical company — let's talk now, not in September.

Navigate regulatory complexity with confidence.

Sources and Further Reading

• Controlled Substances Regulations: SOR/2025-242 — Canada Gazette, Part II, Vol. 159, No. 26
• Regulations Amending the Cannabis Regulations (Harmonization): SOR/2025-244
• Justice Laws Website — SOR/2025-242 Full Text
• Controlled Drugs and Substances Act
• Health Canada — Controlled substances and precursor chemicals

Disclaimer: This article provides general regulatory commentary based on publicly available information about SOR/2025-242 and accompanying instruments. It is not legal advice. For organization-specific guidance on CSR transition readiness, contact MFLRC at info@mflrc.com.